A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
Hoffmann-La Roche
15,000 participants
Aug 27, 2020
OBSERVATIONAL
Conditions
Summary
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
Eligibility
Inclusion Criteria4
- Participant is an adult (according to the age of majority as defined by local regulations)
- Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
- Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
- Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
Exclusion Criteria1
- Participant has a prior or current diagnosis of haematological malignancy
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(138)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04529122